drug · small molecule
orforglipron calcium
Marketedupdated 6mo agoby Eli Lilly and Co🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7Small molecule drug with a maximum clinical stage of Unknown (across all indications), with 3 investigational indications.
indications
investigational
Type 2 DiabetesObesity
all catalysts(1)
News(10)
- Blackstone bets $1.5B on Pfizer’s obesity drugThe deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.biopharma_dive · 6d ago
- Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked NovemberNovartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…biospace · 8d ago
- FDA orders class-wide GLP-1 label update to include potential risk for rare eye diseaseTwelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.biospace · 9d ago
- Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3If approved, the oral GLP-1 would be Eli Lilly’s second marketed drug for obstructive sleep apnea after the GIP/GLP-1 injectable Zepbound secured the first approval in the space in December 2024.biospace · 9d ago
- STAT+: Heart association meeting’s readout is trending ‘neutral’The theme of the American Heart Association meetings was "neutral" results. Yet no one wants to stop pursuing inflammation or Lp(a) lowering.stat · 9d ago
- STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studiesEli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in two late-stage studies, but it doesn’t appear as effective as Lilly’s injectable drug Zepbound.stat · 9d ago
- Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step downThe deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.biopharma_dive · 12d ago
- This week in charts: 3 drug launches Wall Street is watchingThe latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of medicines highlighted in quarterly earnings this week.biopharma_dive · 13d ago
- Novo gets much-needed lift as Wegovy pill tops Wall Street forecastsThe drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines.biopharma_dive · 14d ago
- Novo, Lilly battle for oral GLP-1 dominance with data tit for tatNovo CEO Mike Maziar Doustdar insists that his company is ahead of fierce rival Eli Lilly as oral Wegovy rises to 8 million total prescriptions since its January launch.biospace · 15d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that